Lv626
2140 积分 2025-09-27 加入
Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies
2个月前
已完结
Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System
2个月前
已完结
Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
2个月前
已完结
Adverse reactions of PD-1/PD-L1 inhibitors in cancer: FEARS database analysis and protocols to mitigate immune-related events in elderly patients and when using pembrolizumab and atezolizumab
2个月前
已完结
Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System
3个月前
已完结
Hematological toxicities in antibody–drug conjugates related with breast cancer: a pharmacovigilance study using FDA adverse event reporting system database
3个月前
已完结
Role of sacituzumab govitecan in solid tumors
3个月前
已完结
Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
3个月前
已完结
Mining and influencing factors analysis of sacituzumab govitecan adverse drug event based on FAERS database
5个月前
已完结
Targeting TROP2 Across Solid Tumors: The Clinical Profile and Role of Datopotamab Deruxtecan
5个月前
已完结
皖公网安备34019202002308
